Universal Flu Vaccine Succeeds in Phase 3 Trials, Could End Annual Shots

The era of annual flu shots may be coming to an end. Results from a 25,000-participant Phase 3 trial show that a single dose of the FluShield vaccine provides 88% protection against all known influenza strains for a minimum of three years. The vaccine targets a highly conserved stalk region of the hemagglutinin protein that remains stable across viral mutations.

"This is what we've been chasing for 50 years," said Dr. Sarah Gilbert of the University of Oxford, who was not involved in the study. "A flu vaccine you take once every few years instead of every autumn changes the entire public health equation." The WHO estimates influenza kills up to 650,000 people annually; broad and durable protection could save hundreds of thousands of lives each year. Regulatory submissions are expected in the second half of 2026.

“Results from a 25,000-participant Phase 3 trial show that a single dose of the FluShield vaccine provides 88% protection against all known influenza strains for a minimum of three years.”